Lupin, the second largest pharma company in India with sales above Rs.17,000 crore, has received the establishment investigation report (EIR) from US FDA for the successful inspection of its Pithampur, Unit 1. The inspection was conducted in July 2017.

Nilesh Gupta, managing director, said, “The successful outcome of this inspection is encouraging, and further validates our commitment to meeting global manufacturing standards. We are committed to upholding the highest levels of quality and compliance standards across all out facilities.”

Lupin scrip moved up by 3.7 per cent or Rs.29.20 in the afternoon on BSE to Rs.815.20. The scrip movements were under pressure due to US FDA action for long time. The scrip touched to its day's highest level at Rs.842.45. Lupin share of Rs.2 each reached at it's yearly high at Rs.1,465 during April 7, 2017.